AMNIOGRAFT® and PROKERA® are procured and processed according to Good Tissue Practices (GTP) regulations and Good Manufacturing Practices (GMP) regulations established by the United States Food and Drug Administration (FDA). Placental tissues are retrieved from donor mothers after elective cesarean section under full informed consent. The donor mothers are screened at delivery for infectious, malignant, neurological and auto-immune diseases and other exposures or social habits to determine the suitability for human transplantation. Donors are tested by a CLIA certified independent laboratory using FDA licensed test kits around the time of delivery and found to be serologically negative for, at minimum, the following tests:
|
HIV 1 & HIV 2 antibody HIV 1 Virus (NAT) Hepatitis B surface antigen (HBsAg) Hepatitis B core antibody (HbcAb) |
Hepatitis C Virus (NAT) HTLV I & 2 antibodies Syphilis (RPR) West Nile Virus, WNV, (NAT) | Amniotic membrane is processed using a validated, proprietary method to produce AMNIOGRAFT® and PROKERA® . The final product is released after microbiological testing. AMNIOGRAFT® and PROKERA® are preserved in a validated and patented storage medium. No preservatives have been added. |